Long-term azithromycin reduces COPD exacerbations

In this trial of COPD patients with recent exacerbation, and on oxygen or steroids in the last year, they were randomized to daily azithromycin (250mg) or placebo. Those on azithromycin had significantly fewer exacerbations (1.5 vs 1.8 per patient year) and longer time to first exacerbation (266 vs 174 days). Mortality was the same, but azithromycin-resistant strains were higher. For some severe COPD patients, daily azithromycin may be beneficial, but long term consequences are unknown (abstract)

This entry was posted in ID, Pulmonary and Critical Care. Bookmark the permalink.

Comments are closed.